Noninvasive Assessment of Melasma Pathological Features: Side‐By‐Side Comparison of Two‐Photon Microscopy and Reflectance Confocal Microscopy
Pigment Cell & Melanoma Research · 2025
DOI: 10.1111/pcmr.70057 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Xiaoli Ning und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, China-Japan Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Melanosis. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Beijing Chaoyang Digital Health Proof of Concept Project.
Abstract (Originalsprache)
Melasma, a refractory hyperpigmentation disorder, requires noninvasive tools for accurate pathological assessment. This study compared two‐photon microscopy (TPM) and reflectance confocal microscopy (RCM) for the in vivo characterization of melasma pathology. In this cross‐sectional study, TPM and RCM features and imaging clarity were evaluated in 130 melasma patients. Spearman correlation analyses were performed between TPM‐quantified epidermal melanin, the melanin index (MI), and the individual typology angle (ITA). Features were also compared between active and stable disease stages. TPM and RCM showed substantial agreement in detecting increased epidermal melanin (κ = 0.651), activated melanocytes at the dermal‐epidermal junction (DEJ) (κ = 0.711), and flattened rete ridges (κ = 0.691) (all p < 0.001). TPM excelled in visualizing intracellular melanin distribution, pendulous melanocytes under the DEJ, and solar elastosis, while RCM better identified activated melanocytes at the DEJ. TPM‐quantified epidermal melanin content correlated positively with MI and negatively with ITA. RCM‐detected dermal inflammatory cells were more prevalent in active than in stable melasma. In conclusion, TPM and RCM synergistically capture critical melasma features, with TPM assessing disease severity via epidermal melanin quantification, whereas RCM reflects disease activity by detecting inflammatory cells. This provides clinicians with tailored imaging tools for precision management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Dermatology, China-Japan Friendship Hospital, Beijing, China.
- Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- NHC Key Laboratory of Clinical Big Data Standardization & Integration, Beijing, China.
ORCID-Profile: Xiaoli Ning, Hongfei Ouyang, Ziyuan Tian, Yujun Sheng, Xianbo Zuo, Yong Cui
Förderung
- National High Level Hospital Clinical Research Funding
- Beijing Chaoyang Digital Health Proof of Concept Project
Zitieren
APA
Ning, X., Yang, J., Ouyang, H., Jiang, L., Han, J., Tian, Z., Xu, J., Sheng, Y., Zuo, X., & Cui, Y. (2025). Noninvasive Assessment of Melasma Pathological Features: Side‐By‐Side Comparison of Two‐Photon Microscopy and Reflectance Confocal Microscopy. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.70057
Vancouver
Ning X, Yang J, Ouyang H, Jiang L, Han J, Tian Z, et al. Noninvasive Assessment of Melasma Pathological Features: Side‐By‐Side Comparison of Two‐Photon Microscopy and Reflectance Confocal Microscopy. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.70057
BibTeX
@article{Ning2025,
author = {Ning, Xiaoli and Yang, Jungang and Ouyang, Hongfei and Jiang, Lingfan and Han, Jiahui and Tian, Ziyuan and Xu, Jingkai and Sheng, Yujun and Zuo, Xianbo and Cui, Yong},
title = {Noninvasive Assessment of Melasma Pathological Features: Side‐By‐Side Comparison of Two‐Photon Microscopy and Reflectance Confocal Microscopy},
journal = {Pigment Cell & Melanoma Research},
year = {2025},
doi = {10.1111/pcmr.70057}
}
EUVIMED